Rhode Island is currently home to 495 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT04792502
Recruiting
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Insitute, Providence, Rhode Island
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
Register for Updates
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
03/18/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181
Recruiting
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/18/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Teratoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Stage I Testicular Seminoma AJCC v6 and v7
Register for Updates
Project: Every Child for Younger Patients With Cancer
NCT02402244
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
03/18/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm, Adrenal Gland Pheochromocytoma, Malignant Neoplasm, Neoplasm of Uncertain Malignant Potential
Register for Updates
A New Clinical Model for the Engagement of Latinx Youth with Suicidal Behavior
NCT06882798
Recruiting
This study will test a model of providing treatment to Latinx/Hispanic youth, who experience suicidal thoughts and behavior, and their caregivers. An affirmative and culturally relevant treatment will be provided to all youth and half of the families will be assigned to the additional support of a community health worker (CHW). Youth symptoms and family engagement to treatment will be followed for nine months. The potential benefit of adding the CHW intervention will be assessed.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
03/17/2025
Locations: Bradley Hasbro Children's Research Center, Providence, Rhode Island
Conditions: Suicide Ideation, Suicidal Behaviors, Depressive Symptoms
Register for Updates
Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)
NCT06875622
Recruiting
The purpose of this trial is to compare two delivery formats for weight loss (automated online program vs. group-based videoconference program) and to examine the added effect of individual coaching (vs. no coaching) for individuals with overweight or obesity. All participants enrolled in this study will receive a 12-month behavioral weight loss program (varying in delivery format and individual support), and will be provided with weight loss, calorie intake, and exercise goals. Assessments will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: The Miriam Hospital's Weight Control and Diabetes Research Center, Providence, Rhode Island
Conditions: Obesity/therapy
Register for Updates
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
NCT05677880
Recruiting
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Brown University, Providence, Rhode Island
Conditions: CADASIL
Register for Updates
Study of DF1001 in Patients with Advanced Solid Tumors
NCT04143711
Recruiting
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Solid Tumor, Adult
Register for Updates
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
NCT04068194
Recruiting
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Smilow Cancer Hospital Care Center - Westerly, Westerly, Rhode Island
Conditions: Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333
Recruiting
This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Gliosarcoma, Recurrent Glioblastoma
Register for Updates
Study of DF6215 in Patients with Advanced Solid Tumors
NCT06108479
Recruiting
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Lifespan - Rhode Island Hospital, Providence, Rhode Island
Conditions: Solid Tumor, Adult, Solid Tumor Cancer
Register for Updates
A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer
NCT05902988
Recruiting
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Women & Infants Hospital, Providence, Rhode Island
Conditions: Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Register for Updates